Download - Final 14th
-
8/8/2019 Final 14th
1/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
PREFACE
MBA with specialization in finance is a stepping stone to carry out the financial management in
order to achieve practical, positive and concrete business objectives. The classroom learning
needs to be effectively suited to realities of the situation existing outside the classroom and it is
necessary that the theoretical knowledge must be submitted with exposure to real environment.
So I did my training in a professionally managed organization in Ranbaxy labs Ltd in their
finance department.
The summer internship program was all the more a learning experience for me. Apart from
working on my project, I worked with staff of the organization and got to understand the real
work time conditions and learnt them.
In the report, I will be explaining the Financial Analysis of Ranbaxy in comparison with its
immediate competitors and the Industry Standards. In addition to that a brief explanation of the
prominent activities performed where I contributed to the workings of the organization would be
given.
Studying these, I have attempted to make certain suggestions for the improvements in the
system which I feel if implemented can go a long way in improvising the procedures thereby
enhancing the efficiency.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 1
-
8/8/2019 Final 14th
2/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
EXECUTIVE SUMMARY:
As a part of the SIP, I have been working in the Accounts department at Ranbaxy Labs i.e. the
Payables Department.
Basically, the project work is concentrating on the Financial Analysis of the Company. It is the
study of financial position of the company ascertained through calculating their financial ratios
and their interpretations. The first assignment of the summer internship program was the job of
Invoice Verification assigned to me. Therefore, apart from the project work, an additional
assignment has been included in this Final report.
Payables: At the payables section of the CMA department, I learnt the complete Procurement
process of goods and worked on Invoice verification for three months. It is a SAP based
integrated system and here at the CMA, Ranbaxy releases payments to the vendors for their
plants country-wide, so it was essential to understand how payments are made to the vendors
after invoice verification. The process starts from running the MRP by the Purchase department,
procuring goods till the final payment is released for the vendors.
Invoice Verificationbroadly deals with the matching of the Invoice details with that of the PO
(Purchase Order) details. The PO details are reflected in the liabilities for expenses as they
appear in the SAP system. When original invoices reach the CMA (Centralized Manufacturing
Accounts) department at the Mohali plant, they are taken for invoice verification provided theconsignment clears the Quality Testing stage.
As regards the benefits of using SAP for IV (Invoice verification), they are apparently clear
when we go through the process of IV.
After learning the Creditors management at Ranbaxy, I decided to take up a project of
analyzing the Financial Analysis at Mohali Plant which is into API Business (Business Area
1000). I have practically understood and worked upon the creditors management of the Bulk
drug business concentrating mainly on the Mohali Plant.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 2
-
8/8/2019 Final 14th
3/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
ACKNOWLEDGEMENT
I would take the opportunity to thank my Faculty guide, Prof. Kewal Raj whose valuable
guidance time to time helped me in deciding upon the direction and target of the Internship.
I am grateful to Ranbaxy Laboratories Ltd., team Mohali for the successful completion of the 3
months Summer Internship Program at the CMA (Centralized Manufacturing Accounts)department at the Registered Office of their organization.
I dotingly thankMr. P.N.Singla, General Manager - Accounts and my company
guide for his valuable guidance for the completion of the summer Internship. He assigned me
the jobs which were contributing to my project work and gave me practical learning about the
workings at the department as well.
I am deeply thankful to Mr. Ravinder Chauhan (Sr. Manager) and Mr. Rajiv
Soni (Manager) for their guidance and help in procurement of the required information for
my project and the jobs Iwas assigned.
I also express my deep gratitude to the Human Resources department of the organization with
thecooperation of which I got the opportunity to take up the Summer Internship in their
esteemedorganization.
In the CMA department, it was the extreme cooperation of the staff members that I was able to
learn a lot about the practical aspects and got an opportunity to work for the regular affairs and
get a real time experience. The completion of the project was a not an individual but indeed a
joint effort of all the staff members.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 3
-
8/8/2019 Final 14th
4/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
ContentsPREFACE.......................................................................................................................................1
EXECUTIVE SUMMARY:...........................................................................................................2
ACKNOWLEDGEMENT..............................................................................................................3
INTRODUCTION..........................................................................................................................5
CORPORATE PROFILE OF THE COMPANY............................................................................6
TEN YEARS AT GLANCE.........................................................................................................13
OBJECTIVES OF THE PROJECT..............................................................................................15
LIMITATIONS OF THE PROJECT............................................................................................15
DETAILED DESCRIPTION OF THE PROJECT:......................................................................16
FINANCIAL ANALYSIS:...........................................................................................................16
RATIO ANALYSIS......................................................................................................................18
1. LIQUIDITY RATIOS........................................................................................................18
2. ACTIVITY RATIOS:............................................................................................................23
3. SOLVENCY RATIOS.......................................................................................................30
4. PROFITABILITY RATIOS..................................................................................................41
OBJECTIVE:................................................................................................................................48
INVENTORY MANAGEMENT.................................................................................................49
ROLE OF SAP BASED ERP IN THE INVOICE VERIFICATION:..........................................53
INVOICE VERIFICATION.........................................................................................................54
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 4
-
8/8/2019 Final 14th
5/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
PROCESS OF INVOICE VERIFICATION:................................................................................57
LIMITATIONS & SHORT-COMINGS.......................................................................................69
RECOMMENDATIONS..............................................................................................................70
Freight Clearing:...........................................................................................................................67
ANNEXURES..................................................................................................................................
References:........................................................................................................................................
Freight Clearing:
INTRODUCTION
INTRODUCTION TO THE PHARMACEUTICAL INDUSTRY
Pharmaceutical is one of the most intense knowledge driven industries, which is continuously
in a state of dynamic transition. Driven as complex matrix of processes, operations and
organizations involves in the discovery, development and manufactures of drugs and
medications, the pharmaceutical industry is a life line industry which plays a very crucial role in
building a strong human capital of a country and is a very for economic growth and
development. Indian pharmaceutical industry is mounting up the value chain. From a being pure
reverse engineering industry focused on the domestic market. The industry is moving towards
basic research driven, export oriented global presence, providing wide range of value added
quality products and services.
TheIndian pharmaceutical industry is a success story providing employment for millions and
ensuring that essential drugs at affordable prices are available to the vast population of this
sub-continent.
The Indian pharmaceutical industry today is in the front rank of Indias science based
industries with wide ranging capabilities in the complex field of drug manufacture and
technology. A highly organized sector, the Indian Pharma Industry is estimated to be the worth$4.5 billion, growing at about 8 to 9 percent annually. It ranks very high in the third world, in
terms of technology, quality and range of medicines manufactured.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 5
-
8/8/2019 Final 14th
6/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
Playing a key role in promoting and sustaining development in the vital field of medicines,
Indian Pharma Industry boasts of quality producers and many units approved by regulatory
authorities in USA and UK. International companies associated with this sector have stimulated,
assisted and spearheaded this dynamic development in the past 53years and helped to put India
on the pharmaceutical map of the world.
The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units. It
has expanded drastically in the last two decades. The leading 250 pharmaceutical companies
control 70% of the market with market leader holding nearly 7% of the market share. It is an
extremely fragmented market with severe price competition and government price control.
CORPORATE PROFILE OF THE COMPANYRanbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated,
research based, international pharmaceutical company, producing a wide range of quality,
affordable generic medicines, trusted by healthcare professionals and patients across
geographies. It is ranked among the top 10 global generic pharma companies; Ranbaxy todayhas a presence in 23 of the top 25 pharma markets of the world. The Company has a global
footprint in 49 countries, world-class manufacturing facilities in 11 countries and serves
customers in over 125 countries.
Earlier in June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator
companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical
powerhouse. The transformational deal will place Ranbaxy in a higher growth trajectory. The
ranking of the combined entity will be catapulted to the No. 15th position in the global
pharmaceutical space and it will emerge stronger in terms of its global reach and in its
capabilities in drug development and manufacturing.
MILESTONES OF RANBAXY
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 6
-
8/8/2019 Final 14th
7/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
The company was incorporated in the year 1961.
In 1973, the company went public and a multi-purpose plant was installed in Mohali for
the production of APIs
In 1977, Ranbaxy entered into its first joint venture in Lagos(Nigeria)
A modern plant for Dosage Form was established in Dewas (M.P)
The Research foundation of Ranbaxy was established in 1985
The new Research Centre at Gurgaon, (near Delhi), became fully Operational in1994
In 1998, Ranbaxy entered USA, Worlds largest pharmaceutical market, with products
under its own name
In 2008, Japan's Daiichi Sankyo co. took the majority (50.1%) stake in Ranbaxy, with a
deal valued at about $4.6 billion
VISION
The company is driven by its vision to achieve significant business in proprietary prescription
products by 2012 with a strong presence in developed markets. It aspires to be amongst the top 5
global generic players and aims at achieving global sales of US $5 Billion by 2012.
STRATEGYRanbaxy is focused on increasing the momentum in the generics business in its key markets
through organic and inorganic growth routes. It continues to evaluate acquisition opportunities
in India, emerging and developed markets to accentuate its business and competitiveness. The
Companys growth is well spread across geographies with near equal focus on developed and
emerging markets. Ranbaxy has entered into new specialty therapeutic segments like
biosimilars, oncology, peptides and limuses. These new growth areas will add significant depth
to its existing product pipeline.
RESEARCH AND DEVELOPMENT
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 7
-
8/8/2019 Final 14th
8/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
Ranbaxy views its R&D capabilities as a vital component of its business strategy that will
provide the company with a sustainable, long-term competitive advantage. The Company today
has a pool of over 1,200 scientists engaged in path-breaking research.
Ranbaxy is among the few Indian pharmaceutical companies in India to have initiated its
research program in the late 70s. To support its global ambition, a first of its kind world class
R&D centre was commissioned in 1994. Today, the Companys multi-disciplinary R&D centre
at Gurgaon, in India, houses dedicated facilities for generics research and innovative research.
The Companys robust R&D environment for both drug discovery & development reflects the
Companys commitment to be a leader in the generics space and offer value added formulations
based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research
outcomes.
Ranbaxy has enhanced its focus on NCE research with the proposed De-merger of its New DrugDiscovery Research (NDDR) unit into a separate entity, Ranbaxy Life Science Research Ltd,
subject to requisite approvals. This significant step will open up new growth opportunities and
provides a platform for increased collaboration.
The new drug research areas at Ranbaxy include anti-infectives, inflammatory / respiratory,
metabolic diseases, oncology, urology and anti-malaria. Presently, the Company has 8-10
programs comprising one anti-malaria molecule in Phase-II clinical trials. The Company has
two programs in Phase I and the remaining in the pre-clinical stage. This includes a
collaborative research program with GSK.
The company's NDDS focus is mainly on the development of NDA/ANDAs of oral controlled-release products for the regulated markets. The Companys first significant international success
using the NDDS technology platform came in September 1999, when Ranbaxy out-licensed its
first once-a-day formulation to a multinational company.
MANUFACTURING FACILITIES
RANBAXY possesses the manufacturing strengths that have established it as a producer of
world-class generics, branded genericsand a major supplier of its range ofActive
Pharmaceutical Ingredientsfor pharmaceutical products of companies worldwide.
Ranbaxy has world-class manufacturing facilities in 11 countries namely:
1. Brazil
2. China
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 8
-
8/8/2019 Final 14th
9/70
-
8/8/2019 Final 14th
10/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
BOARD OF DIRECTORSAt the helm of the entire operations is the experience and able direction of the people who make
it all happen. Ranbaxy acknowledges their inspiring stewardship and indefatigable work.
Board of Directors
Standing (left to right) :Mr Ramesh Adige, Mr Vinay K Kaul, Mr
Ravi Mehrotra, Dr Brian W Tempest, Mr Vivek Bharat Ram, Dr P S
Joshi, Mr Malvinder M Singh, Mr Surendra Daulet-Singh, Mr
Shivinder M Singh, Mr Atul Sobti
Sitting (left to right) : Mr Nimesh Kampani, Mr Harpal Singh, Mr
Tejendra Khanna*, Mr Vivek Mehra, Mr Gurcharan Das
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 10
-
8/8/2019 Final 14th
11/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
Mr. Harpal Singh, Non-executive
Chairman
Dr. Brian W. Tempest
Mr. Malvinder Mohan Singh
Mr. Atul Sobti
Mr. Ramesh L. Adige
Mr. Vinay. K. Kaul
Mr. Shivinder Mohan Singh
Dr. P. S. Joshi
Mr. Surendera Daulet-Singh
Mr. Vivek Bharat Ram
Mr. Nimesh N Kampani
Mr. Vivek Mehra
Mr. Gurcharan Das
Mr. Ravi Mehrotra
Mr. Sunil Godhwani
* Mr. Tejendra Khanna has been appointed as the Lt. Governor
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 11
http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=7&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=7&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=7&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=1&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=1&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=2&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=2&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=58&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=58&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=3&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=3&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=21&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=21&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=54&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=54&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=13&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=13&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=14&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=14&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=15&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=15&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=16&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=16&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=18&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=18&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=19&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=19&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=55&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=55&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=67&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=67&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=7&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=7&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=1&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=2&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=58&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=3&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=21&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=54&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=13&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=14&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=15&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=16&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=18&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=19&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=55&flag=http://www.ranbaxy.com/aboutus/team_dispnew.aspx?id=67&flag= -
8/8/2019 Final 14th
12/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
of Delhi (India). As a consequence, he stepped down from the
position of the Chairman and Director on the Board of the
Company on April 8, 2007. Subsequently Mr. Harpal Singh has
been appointed as the Chairman w.e.f April 27, 2007.
VALUES
Achieving customer satisfaction is fundamental to their business.
Practice dignity and equity in relationships and provide opportunities for
people to realize their full potential. Ensure profitable growth and enhance wealth of shareholders.
Foster mutually beneficial relationships with all their business partners.
Manage their operations with company for safety and environment.
OBJECTIVES OF RANBAXY
LABORATORIES
To be a leader in Pharmaceutical industry.
To be a profitable company with a steady gowth in earnings.
To set an example as a socially responsible company.
To diversify in health care related areas.
To strive for excellence and continuous improvement in all spheres.
To improve the quality of life of people by providing better services and
quality products.
To provide a harmonious environment at the work place this helps in
developing the potential of the employees.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 12
-
8/8/2019 Final 14th
13/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
FINANCIAL
POSITION
TEN YEARS AT GLANCE
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 13
-
8/8/2019 Final 14th
14/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
SOURCE: Data from annual report (Balance Sheet), 2003-07
SOURCE: Data from annual report (Balance Sheet), 2003-07
Though the sales of the company had been on a constant increase over the last 10 years, there
was a sudden fall in Profit After Tax (PAT-Profit available to the Equity holders and the
organization itself) in 2004 & 2005. The key reason for the sudden fall in PAT can be attributed
to the sudden hike in Selling &Administration costs.
OBJECTIVES OF THE PROJECT
(1)To study the Financial Analysis of Ranbaxy in comparison with its immediate competitors
and the industry standards.
(2)To find factors responsible for the changes in the financial position of the company
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 14
-
8/8/2019 Final 14th
15/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
(3) To analyze the various functions and procedures followed by the company in Centralized
Manufacturing Accounts (CMA) department by various accounting officials in dealing with the
accounting process
4) To learn the System Application Products (SAP), computer software adopted by the company
specifically for the purpose integrated accounting system.
LIMITATIONS OF THE PROJECT
1) Restrictive analysis is conducted due to the shortage of the time allotted to the study period.
2) Lack of inadequate information as the company cannot allow a trainee to undertake its
accounts work as it is a matter of financial information of the company
DETAILED DESCRIPTION OF THE PROJECT:
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 15
-
8/8/2019 Final 14th
16/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
FINANCIAL ANALYSIS:
Financial analysis is the process of identifying the financial strengths and weaknesses of the
company by properly establishing relationships between the items of the balance sheet and the
profit and loss account.
Management should be particularly interested in knowing financial strengths of the company to
make their best use and to be able to spot out financial weaknesses of the company to take
suitable corrective actions. Thus, financial analysis is the starting point for making plans, before
using any sophisticated forecasting and planning procedures. In this manual Ratio Analysis of
Ranbaxy Laboratories Ltd. is been calculated to analyze companys past performance and to
assess its present financial strengths. Ratio analysis is considered as a widely used technique to
evaluate the financial position and performance of a business.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 16
-
8/8/2019 Final 14th
17/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
TYPES OF RATIOS
RATIO ANALYSIS
1. LIQUIDITY RATIOS
Liquidity refers to the ability of a company to meet its current obligations. These are the ratios
which measure the short term solvency or financial position of a company. A company should
ensure that it does not suffer from lack of liquidity. To measure the liquidity of a company, the
following ratios can be calculated.
1.1CURRENT RATIO
Current ratio is defined as a relationship between the current assets and the current liabilities. It
is also known as the working capital ratio and it is a measure of general liquidity and is used to
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 17
TYPES OF RATIOS
-
8/8/2019 Final 14th
18/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
make the analysis of a short term financial position or liquidity of the company. A ratio equal or
near to the rule of thumb of 2:1 i.e., current assets double the current liabilities is considered to
be satisfactory.
SOURCE: Data from www.moneypore.com and calculationsdone in annexure
SOURCE: Data from annual report (Balance Sheet), 2003-07
INTERPRETATION
The current ratio of Ranbaxy has been compared with the stop three pharmaceutical
organizations for the year 2007 and the Current Ratio of Ranbaxy itself has been compared with
its own for the last five years. As per the above inter firm comparison, we can see that
Ranbaxys current ratio is not near to the rule of thumb i.e., 2:1 and its having the lowest of the
Current Ratio in the above selected top four Indian Pharmaceutical companies. The major reason
for depleting of Ranbaxys current ratio is due to their increase in current liabilities. Their
increase in current liabilities is more than their increase in current asset.
The ideal current ratio to be maintained by the pharmaceutical cannot be accurately assessed
because the scale of operations and the inventory size has been different for all the companies in
the industry. The current ratio of Ranbaxy has thus been compared with the industry standards.
The industry standards have been calculated taking the average of top 4 pharmaceuticals of
India.
Note: Calculations attached in the annexure
Asper the above comparison, the Current ratio maintained by Ranbaxy is although near a
general notion of an ideal Current ratio but way below the normal Industry standards. The
reason for a lower Current ratio is the heavy amount of Current liabilities incurred mainly due to
the Creditors resulting from a long payables deferral period.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 18
http://www.moneypore.com/http://www.moneypore.com/ -
8/8/2019 Final 14th
19/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
1.2QUICK RATIO
Quick Ratio is also known as the Acid Test Ratio. It is a more conservative measure of liquidity.
Quick ratio measures those assets which are immediately converted into cash without much loss.
Quick assets include all current assets except inventories and prepaid expenses.
SOURCE: Data from www.moneypore.com and calculationsdone in annexure
SOURCE: Data from annual report (Balance Sheet), 2003-07
INTERPRETATIONA high ratio indicates under stocking and low ratio indicates over stocking. Stock is excluded
because it may take time to be converted into cash. Quick ratio measures those assets, which are
immediately converted into cash without much loss, though there is no way to measure an ideal
quick ratio but as a rule of thumb, it should be at least 1:1.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 19
http://www.moneypore.com/http://www.moneypore.com/ -
8/8/2019 Final 14th
20/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
For the same reason that different pharmaceuticals in the industry cannot be compared on
common grounds, an industry average has been calculated for the top 4 companies (ranked by
their sales).
Note: Calculations attached in the annexure
From the above comparison, it can be inferred that a comparatively heavy
amount of investment has been made in the inventories. This is because
although the Quick Ratio maintained by Ranbaxy is very near a said ideal
ratio of 1:1 but that way below the Industry standards. On comparative
terms Quick Ratio is lower than the Industry standards than Current ratio is
below the Industry Standards. Moreover, it can be clearly viewed from the
Balance Sheet the Current Assets has always been invested in Stock (Copyof Balance Sheet attached in the Annexure).
2. ACTIVITY RATIOS:Activity ratios are calculated to measure the efficiency with which the resources of a company
have been employed. These ratios are also called the turnover ratios because they indicate the
speed with which assets are being turned over into sales. The various turnover ratios are:
2.1 TRADE RECEIVABLES TURNOVER RATIO
It is also known as Debtors turnover ratio. It indicates the velocity of debt collection of
company. The shorter the average collection period, the better the quality of debtors, as a shortcollection period implies the prompt payments by debtors.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 20
-
8/8/2019 Final 14th
21/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
SOURCE: Data from www.moneypore.com and calculations done in annexure
SOURCE: Data from annual report (Balance Sheet), 2003-07
INTERPRETATION
Debtors velocity indicates the number of times the debtors are turned over during a year. There
is no rule of thumb which may be used as a norm to interpret the ratio as it is different from
company to company, depending upon the different receivable period policies of the business.
For the same reason that different pharmaceuticals in the industry cannot be compared on
common grounds, an industry average has been calculated for the top 4 companies (Ranked by
their turnovers).
Note: Calculations attached in the annexure
From the above comparison, it can be inferred that Ranbaxys debtor turnover ratio has always
been higher than the required industry standards. This indicates that the company is very muchefficient in the management of its Debtors/Sales or, more liquid are the debtors.
2.2 INVENTORY TURNOVER RATIO
Inventory turnover ratio is also known as stock velocity. It would indicate whether inventory has
been efficiently used or not. The purpose is to see whether only the required minimum funds
have been locked up in inventory.
SOURCE: Data from www.moneypore.com and calculationsdone in annexure
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 21
http://www.moneypore.com/http://www.moneypore.com/http://www.moneypore.com/http://www.moneypore.com/ -
8/8/2019 Final 14th
22/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
SOURCE: Data from annual report (Balance Sheet), 2003-07
INTERPRETATION
Inventory turnover ratio measures the velocity of conversion of stock into sales. There is no
rules of thumb or standard inventory turnover ratio for interpreting the inventory turnover
ratio. The norms maybe different for different companies depending upon the nature of industry
and business conditions.
Note: Calculations attached in the annexure
From the above comparison, we can conclude that Ranbaxys inventory turnover ratio is almost
near to the required Industry Standards. So we can say on the basis of above graph that the
company is efficiently managing its inventory because more frequently they sold their stocks so
the lesser amount of money is required to finance the inventory.
2.3 SALES TO WORKING CAPITAL RATIO:It is a measurement comparing the depletion of working capital to the generation of sales over agiven period. This provides some useful information as to how effectively a company is using its
Working Capital to generate sales.
SOURCE: Data from www.moneypore.com and calculationsdone in annexure
SOURCE: Data from annual report (Balance Sheet), 2003-07
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 22
http://www.moneypore.com/http://www.moneypore.com/ -
8/8/2019 Final 14th
23/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
INTERPRETATION
A company uses working capital to fund its operations and purchase inventory. These
operations and inventory are then converted into sales revenue for the company. The working
capital turnover ratio is used to analyze the relationship between the money used to fund
operations and the sales generated from these operations.
In a general sense, the higher the working capital ratio, the better it is because it means that the
company is generating a great degree of sales as compared to the money it utilizes to fund the
sales.
Note: Calculations attached in the annexure
From the industry comparison, it is apparent that Ranbaxys Working Capital Turnover Ratio
has always been above Industry standards which implies that the sales generated by Ranbaxy
has always been much higher than the cost incurred to generate those sales as compared to other
pharmaceutical giants in the Industry.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 23
-
8/8/2019 Final 14th
24/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
3. SOLVENCY RATIOS
The term leverage or solvency refers to the ability of a company to meet its
long term obligations. The long term indebtedness of a company includes debenture holders,financial institutions providing medium and long term loans and other creditors selling goods on
installment basis. Accordingly long term solvency ratios indicate a companys ability to meet
the fixed interest and costs and repayment schedule associated with its long term borrowings.
3.1DEBT EQUITY RATIO:
Debt-Equity ratio also known as External-Internal Equity Ratio is calculated to measure the
relative claims of outsiders and the owners against the companys assets. This ratio indicates the
relationship between the external equities or the outsiders funds and the internal equities or the
shareholders funds.
SOURCE: Data from www.moneypore.com and calculationsdone in annexure
SOURCE: Data from annual report (Balance Sheet), 2003-07
INTERPRETATION:
The Debt-Equity ratio is calculated to measure the extent to which debt has been used in a
business. A ratio of 1:1 may be usually considered to be satisfactory ratio although there cannot
be any rule of thumb or standard norm for all types of business.
For the same reason that different pharmaceuticals in the industry cannot be compared on
common grounds, an industry average has been calculated for the top 4 companies (Ranked by
their turnovers).
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 24
http://www.moneypore.com/http://www.moneypore.com/ -
8/8/2019 Final 14th
25/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
Note: Calculations attached in the annexure
From the above comparison, it can be inferred that from the year 2003-05 the Debt equity ratio
maintained by the Ranbaxy was very low than the industry standards but later on from the year
2006 the Debt-equity ratio of Ranbaxy reached beyond the levels of the Industry standards. So
this indicates that the claims of outsiders are greater than those of owners.
3.2FUNDED DEBT TO TOTAL CAPITALIZATION RATIO
The ratio establishes a link between the long term funds raised from outsiders and total long
term funds available in the business.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 25
-
8/8/2019 Final 14th
26/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
SOURCE: Data from www.moneypore.com and calculationsdone in annexure
SOURCE: Data from annual report (Balance Sheet), 2003-07
INTERPRETATION
Funded Debt is hat part of total capitalization which is financed by the outsiders. Though there
is no rule of thumb but still the lesser the reliance on the outsiders the better it will be. If this
ratio is smaller, better it will be, up to 50% or 55% this ratio may be tolerable and not beyond.
Note: Calculations attached in the annexure
From the industry comparison, it is apparent that Ranbaxys funded debt to total capitalization
ratio is very much higher than the Industry standards in the past two financial years which is
against the norms of this ratio, so it would be advisable to the company that it should not relied
much on outside sources for raising long-term funds.
3.3 PROPRIETARY RATIO
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 26
http://www.moneypore.com/http://www.moneypore.com/ -
8/8/2019 Final 14th
27/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
A variant to the debt-equity is the proprietary ratio also known as Equity Ratio. This ratio
establishes the relationship between the shareholders funds to total assets of the company.
SOURCE: Data from www.moneypore.com and calculationsdone in annexure
SOURCE: Data from annual report (Balance Sheet), 2003-07
INTERPRETATION
This ratio indicates the extent to which the assets of the company can be lost without affecting
the interest of creditors of the company. The general notion of this ratio is, higher the ratio or the
share of the shareholders in the total capital of the company, better is the long-term solvency
position of the company.
Note: Calculations attached in the annexureAs per the above comparison, we can reach to the conclusion that Ranbaxys share of owners is
not up to the required industry standards. So the company, instead of depending on outside
source for raising long term funds, should depend more on Shareholders funds.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 27
http://www.moneypore.com/http://www.moneypore.com/ -
8/8/2019 Final 14th
28/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
3.4 SOLVENCY RATIO:
This ratio is a small variant of equity ratio. The ratio indicates the relationship between the total
liabilities to outsiders to total assets of a company.
SOURCE: Data from www.moneypore.com and calculationsdone in annexure
SOURCE: Data from annual report (Balance Sheet), 2003-07
INTERPRETATION
Solvency ratio is the ratio of total liabilities to total assets. Generally, lower the ratio of total
liabilities to total assets, more satisfactory is the long term solvency position of a company.
Note: Calculations attached in the annexure
From the above comparison, it is apparent that Ranbaxys solvency ratio is much higher than the
Industry standards, which is not a satisfactory one.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 28
http://www.moneypore.com/http://www.moneypore.com/ -
8/8/2019 Final 14th
29/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
3.5INTEREST COVERAGE RATIO:
Net income to interest coverage ratio or simply debt service ratio is used to test the debt-
servicing capacity of a company. The ratio is also known as Debt Service Ratio.
SOURCE: Data from www.moneypore.com and calculationsdone in annexure
SOURCE: Data from annual report (Balance Sheet), 2003-07
INTERPRETATION
Interest coverage ratio indicates the number of times interest is covered by the profits available
to pay the interest charges. Long term creditors are interested in knowing the companys ability
o pay the interest on their long-term borrowing. Generally, higher the ratios, safer are the long
term creditors because even if earnings of the company fall, the company shall be able to meet
its commitment of fixed interest charges.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 29
http://www.moneypore.com/http://www.moneypore.com/ -
8/8/2019 Final 14th
30/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
Note: Calculations attached in the annexure
From the above comparison, it can be inferred that the companys Interest Coverage ratio is
much lower than the required Industry standards, which is not an acceptable position of the
company. So it is advisable to the company to reduce the level of amount of fixed charges they
incurring by reducing their long term debts.
4. PROFITABILITY RATIOS
Profit earning is considered essential for the survival of the business. A business needs profits
not only for its existence but also for expansion and diversification. Profits are thus, a useful
measure of overall efficiency of a business. Generally, profitability ratios are calculated either inrelation to sales or in relation to investment.
4.1GROSS PROFIT RATIO:
It measures the relationship of gross profit to net sales and is usually represented as a
percentage.
SOURCE: Data from www.moneypore.com and calculationsdone in annexure
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 30
http://www.moneypore.com/http://www.moneypore.com/ -
8/8/2019 Final 14th
31/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
SOURCE: Data from annual report (Balance Sheet), 2003-07
INTERPRETATION
The gross profit ratio indicates the extent to which selling prices of goods per unit may decline
without resulting in losses on operations of a company. It reflects the efficiency with which a
company produces its products. The general notion is that higher the G.P. ratio, better the result.
Note: Calculations attached in the annexureFrom the above comparison, we can see that, from the last three years the Ranbaxys gross profit
ratio is not up to the level of Industry standards as it had been in the years 2003& 04. The low
gross profit ratio of the company generally indicating the high manufacturing expense incurred
during the last three years.
4.2OPERATING RATIO:It establishes the relationship of operating profit to net sales and this is also
usually represented in a percentage form.
SOURCE: Data from www.moneypore.com and calculationsdone in annexure
SOURCE: Data from annual report (Balance Sheet), 2003-07
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 31
http://www.moneypore.com/http://www.moneypore.com/ -
8/8/2019 Final 14th
32/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
INTERPRETATION
Operating ratio indicates the percentage of net sales to operating profit. Operating profit ratio
considered to be a yardstick of operating efficiency of the company. There is no rule of thumb
for this ratio as it may differ from company to company depending upon the nature of its
business and its capital structure.
Note: Calculations attached in the annexureFrom the above comparison, we can conclude that in the past years the operating profitability of
the company is above the industry standards, the reason for this was due to the economies of
scale and increase in operations. But in the recent years it is below the industry standards, this isbecause the scale of operation were not profitable so the operating costs incurred on high basis
due to such inefficiencies.
4.3NET PROFIT RATIO:
This ratio indicates the efficiency of the management in manufacturing, selling, administrative
and other activities of the company.
SOURCE: Data from www.moneypore.com and calculationsdone in annexure
SOURCE: Data from annual report (Balance Sheet), 2003-07
INTERPRETATIONThe two basic elements of the ratio are net profits and sales. The ratio is very useful as if theprofit is not sufficient, the company shall not be able to achieve a satisfactory return on its
investment. This ratio also indicates the companys capacity to face adverse economic
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 32
http://www.moneypore.com/http://www.moneypore.com/ -
8/8/2019 Final 14th
33/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
conditions such as price competition, low demand, etc. Obviously, higher the ratio, the better is
the profitability.
Note: Calculations attached in the annexure
From the above comparison, it can be inferred that the net profit ratio of the company is almost
near to the industry standards.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 33
-
8/8/2019 Final 14th
34/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
OBJECTIVE:
At Ranbaxy Laboratories Ltd, In Centralized Manufacturing Accounts (CMA) department,
various tasks are performed pertaining to creation and maintenance of accounts processing of
various expenditures for investment purposes. I am taking up invoice verification under the
guidance of Mr. Gurmeet Wasan, Sr. Executive, Accounts in order to understand the complete
Procurement process of Ranbaxy and how the payments are released for the vendors.
This is related to the management of payables to the creditors i.e. the vendors of the
organization.
Invoice Verification is undertaken in the Payables section of the organization which would make
me understand the Financial Management for the organization apart from their Inventory
Management, a par which I will be taking up separately afterwards.
As a part of the same, I have worked on the Payables Management of the organization. Now, I
will try to understand the Inventory management by understanding the Inventory valuation
techniques.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 34
-
8/8/2019 Final 14th
35/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
INVENTORY
MANAGEMENT
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 35
-
8/8/2019 Final 14th
36/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
In order to understand how inventory control is exercised in Ranbaxy, we need to understand the
complete procurement procedure of the Organization. The procurement of goods in Ranbaxy is
undertaken in the following manner:
Contacting vendors for conveying the Purchase requirements and finalizing the vendor.
Sending the Purchase order (PO) to the vendor.
Purchase order* contains:
The material requirements of the organization
Pricing details of the material to be procured and expenses to be incurred
The consignment as agreed upon by the consignor is sent and received at the warehouse
by the warehouse department of the organization.
The GRN (Goods receipt note) number is generated as soon as the goods (consignment)
are collected. The GRN number is like an entry gate identification code for a particular
batch of goods. This number is assigned by the warehouse in charge of the Purchase
department. The system immediately creates liabilities in the SAP taking up the details
from the Purchase Order as soon as the GRN number is created. Details picked from the
Purchase order refer to the list of pricing, specifications of goods and the relevant
expenses to be incurred for the procurement of goods.
Quality Testing: Goods after receipt and generation of the GRN number are sent forquality testing.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 36
-
8/8/2019 Final 14th
37/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
The goods which are approved by the quality testing department are forwarded to the
plant premises for their usage in production. Invoice verification is performed for the
same goods.
Defective/Rejected goods are held at the warehouse by the Purchase department for
return. In case of Packing Material procured by the organization defective goods are
destroyed by the authorities so that such defective material cannot be used by any other
organization.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 37
-
8/8/2019 Final 14th
38/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 38
-
8/8/2019 Final 14th
39/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
INVENTORY REPORT TO MANAGEMENT
Inventory management refers to managerial functions which are directed to ensure that required
quantity and quality of material is provided at the proper time with the minimum amount of
capital. Inventory control is affected by coordination and control activities relating to planning,
sourcing, purchasing, moving and storing of materials. For proper results, performance in the
field of Inventory control should be properly reported to management. Following points are
covered while reporting the Inventory position to the management:
Number of purchase order placed during the month, cumulative for the year up to the day
of sending the reports.
A calendar of returns should be prepared showing the various reports, time schedule and
the level of management where report is to be sent, periodicity of reports etc.
Separate reports for foreign and local orders.
Details of number of purchase requisitions order placed and number or requisition
pending.
Savings materialized by purchasing at price below market price.
Loss due to wastage, spoilage and obsolescence.
Cost of placing order.
Saving achieved vs. target savings in inventory control.
Cost of running the department.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 39
-
8/8/2019 Final 14th
40/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
ROLE OF SAP BASED ERP IN THE INVOICE VERIFICATION:
An ERP system in a company is a software solution that addresses the enterprise needs taking
the process view of an organization to meet the organizational goal tightly integrating all
function of an enterprise.
Ranbaxy has incorporated well developed ERP system that uses the System Application Product
(SAP) software which helps the company to gain competitive edge by integrating all business
process and optimizing the resource available. It has adopted SAP R/3 version. System
Application Product (SAP) is a product of GERMANY that help in data processing.
NEED FOR AN ERP SYSTEM:
In todays dynamic and turbulent environment, there is a strong need for the organization to
become globally competitive. Enterprise Resource Planning (ERP) is a strategic tool, which
helps the company to gain competitive edge by integrating all business process and optimizingthe resource available.
SAP based ERP system has made the process of Invoice Verification all the more easy for the
CMA department. It is a very systematic auto-check system which verifies all the particulars of
the invoices and matches the same with those mentioned in the Purchase Order and Vice-Versa.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 40
-
8/8/2019 Final 14th
41/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
INVOICE VERIFICATION
PAYABLE MANAGEMENT RANBAXY
Ranbaxy Laboratories Ltd separate Centralized Manufacturing Accounts (CMA) department in
Mohali location, which takes care of payments related to Creditors. The effective control ofdisbursement helps the company in conserving cash and reducing the financial requirements.
Disbursements arise due to trade credit, which is a source of Fund. The company should make
payments using credit terms to the fullest extent. There are two ways:
MIR6- Used for Mass Invoice Verification
MIRO- Used for Individual Invoice Verification for all Invoices
CREDIT TERMS:
Credit terms refer to the conditions under which the suppliers sell on credit to the buyer, and the
buyer is required to repay the credit. These condition include the due date and cash discount (ifany) given for prompt payment. The cash discount can be availed by the buyer if he pays a
certain date which is quite earlier than the due date.
Is trade credit a cost free source of finance?
It appears to be cost free since it does not involve explicit interest charges. But in practice, it
involves implicit cost. The cost of credit may be transferred to the buyer via the increased price
of goods supplied to him. The user of trade credit, therefore, should be aware of the costs of
trade credit to make its intelligent use. The supplier extending trade credit incurs cost in the
form of the opportunity cost.
CHECKING INWARD INVOICES AND PASSING THEM FOR
PAYMENTS
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 41
-
8/8/2019 Final 14th
42/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
Ranbaxy Laboratories Ltd has Centralized Manufacturing Accounts (CMA) at Mohali location
from which invoices are digitally checked and payments are made accordingly. Checking of
Inward Invoice (sellers invoice) is done digitally against quantity specified on the purchase
order and the quantity received as per goods received note. Terms and rate are checked against
the purchase order. If invoice is correct in all respects, the purchase officer will pass it on to
Centralized Manufacturing Section (CMA) section for payment.
INVOICE VERIFICATION
IF DETAILS IN THE VOICES ARE DIFFER FROM THAT OF THEPURCHASE ORDER:
CASE I
If the liabilities created in the SAP system is more than that appearing in the details of the goods
actually procured mentioned in the invoice.
The extra-ordinary liabilities appearing in the system are cleared in name of the organization
itself. This is because the liability towards the expenses is higher as compared to the paymentsactually made to the vendor.
When it comes to incurring the actual liabilities, there are some of the expenses which have been
included but not actually incurred during the procurement of the consignment. But such
expenses keep standing in the books of accounts as liabilities for the company. The debit
balance of such expenses is cancelled by crediting it with an equivalent amount. This credit is
done by the organization in its own name because the actual expenses incurred have already
been paid. The notional figures that are standing in the books of accounts of the company are to
be settled.
CASE II
If the liabilities created in the SAP system are less than the actual liabilities that are to be
incurred.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 42
-
8/8/2019 Final 14th
43/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
The proposed terms in the invoice are negotiated the higher authorities authorized to make any
changes. These authorities can be negotiated with on terms of the rate of the material procured.
These rates can be altered only if agreed upon by the authorized signatories.
If the proposed terms are not agreed upon by the authorities, the invoices are passed on the rates
mentioned in the Purchase order. It may so happen that the vendor may propose for a hike in
prices and the request is agreed upon later on. Now, sometimes the vendor asks for a
retrospective effect but the liabilities generated in the SAP system cannot be altered because
once the liabilities are generated picking up details from the Purchase Order and such liabilities
cannot be altered because that amounts to alteration in the terms of the Purchase which is not
possible at this stage.
RETROSPECTIVE EFFECT:
We need to pass entries in the system manually in order to increase the liability of the vendor
and then debit the expenses by the requisite extra amount in order to meet the liability for
expenses and the balance the Vendor Account as well.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 43
-
8/8/2019 Final 14th
44/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
PROCESS OF INVOICE VERIFICATION:
The process of Invoice verification is an auto-check system for the release of payments to the
respective vendors. The process goes on as follows:
The purchase department updates the details about the status of the goods during their
quality check. These updating are made in the SAP system. Updating refers to which
goods have been passed, which are under test and which have been rejected. The
complete details are mentioned in the SAP and the same can be accessed from the
Accounts department.
Now, we at CMA department, download the current status of the goods on a daily basis.
This status sheet is downloaded as a text file and then later on converted to an excel
spreadsheet. This spreadsheet contains the details of the goods along with their GRN
number. These details include: Date of Posting
Date of invoice
Invoice number
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 44
-
8/8/2019 Final 14th
45/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
Location
Business Area Code
PO number
Vendor code
Vendor name
Delivery Challan number (Excise invoice number). If the goods are excise duty
exempted, the Delivery Challan number is the same as the Invoice number.
Quantity received
Quantity approved
Quantity under test
Quantity rejected
Material name
Material code*
*Material code refers to the coding which is done by the Purchase department to a particular
kind of Material e.g. Material code starting with 2 or 3 refers to the raw material, starting with 4
refers to the engineering products and the codes starting with 5 refer to the Packing Material.
From the lot of the pending invoices, the invoices of which the goods have been passed after the
quality check are forwarded for uploading. This is done by mentioning the total amount of
invoice as mentioned by the vendor.
The line items which have been recently passed are uploaded in the SAP system. This is done bymoving the data of one particular excel spreadsheet to another and then the line items for which
the amounts have been recently updated are sorted and the rest of items are deleted. Now, this
data is set in a particular format in which the ERP system is able to pick up the data. This stage
is crucial because a single error in the format of the data of line items can upload wrong data, no
data or redundant data.
The coding used for the uploading of the recently updated line items is MIRA. The system with
regular supervision uploads all the entries in the ERP system.
After updating, the data is posted in the SAP system using MIR6 code. All the uploaded entries
are posted which the system further carries for verification.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 45
-
8/8/2019 Final 14th
46/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
Now, here at this stage the SAP system tallies the details which are existing in the itself since
the instance of GRN generation with that of the details of invoices uploaded and posted recently
in the system.
If the difference of the two details is less than Rs. 10, the SAP system passes the invoice and
releases the same for payment. On the contrary, if the difference exceeds Rs. 10, the SAP system
blocks the entry and does not post the same. Such entries are taken for verification manually and
differences are reconciled.
If goods are partially approved:
In case, the goods after test are partially approved i.e. a certain lot of goods is rejected, the goods
are returned to the vendor in case of Raw Material (In case of packing material, defectivematerial is destroyed in order to prevent misusage). When goods are returned to the vendor,
payment to the vendor is made on the basis on the information as per the PO as regards the rate
per unit of the material or line item.
As regards the excise duty chargeable, the liability for the excise duty payable gets reduced as
soon as a reverse entry is passed for the return of goods. Along with reduction in the liability of
creditors, all the corresponding expenses also get reduced.
ACCOUNTING PERSPECTIVE
At the time of the procurement of the goods when the GRN number is generated inside the
system, the following accounting entries are passed:
At the time of the procurement:
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 46
-
8/8/2019 Final 14th
47/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
Inventory A/C.dr.
To GRIR A/C
At the time when are goods are drawn for consumption:
Consumption A/C.dr.
To Inventory A/C
At the time of Invoice Verification:
GRIR A/C.dr.
To Vendor A/C
At the time of payment to the Vendor
Vendor A/C..dr.
To Bank A/C
Note: If there is any variation in the rate mentioned in the Purchase order and the rate at which
payment has to be actually made to the vendor, then in the third journal, system makes necessary
changes and adjusts the same to the Consumption A/c and Inventory A/c respectively.
PAYMENT TERMS:
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 47
-
8/8/2019 Final 14th
48/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
The payment terms are defined in terms of payment term codes. These codes refer to the
payment term of a vendor exceeding which time limit, the buyer is required to pay 3 times the
interest of RBI (Reserve Bank of India) on the Bill amount.
Z-032: 30 days
Z-033: 45 days
Z-036: 90 days
Z-037: 120 days
The typical way of expressing credit terms is for example, as follows: 2/45, net 90. This implies
that a 2 percent discount is available if the credit is repaid on or before the 45th day and in case
the discount is not taken, the payment is due by the 90th
day.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 48
-
8/8/2019 Final 14th
49/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
The Initial screen for the start up procedure for updating and posting is as follows:
The Updating and posting can be started in the background by using the last option of
ZMIVBACK.
For mass verification use transaction code ZMIVBACK and save the file in the name of
mirainv. The SAP has Standard format through which system verify the invoice in mass. The
standard format of SAP consists of nine columns which are given below:
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 49
-
8/8/2019 Final 14th
50/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
Invoice
Date
Posting
Date
Bill
No.
Bill
Amt.
GR
No AssignmeBusiness
Area
Challa
No
Vendor
code
After mass verification through System Application Product (SAP) support, same is posted
through mira posting. After this, individual verification is done of those file which SAP hasnot passed in mass verification. After rectifying as per purchase order bill is passed for payment.
IF THE ENTRIES ARE POSTED:
The SAP system gives the details of the entries posted and a list of the same can be displayed
and a hard copy of the same is taken. Now, the 10-digit document number of different invoices
on which they have been posted is marked on the original invoices. This document number is
mentioned so that the details of the invoices can be easily viewed in case there is anydiscrepancy at a later stage. The following screen can be viewed if we enter the FB03
Financial Accounting
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 50
-
8/8/2019 Final 14th
51/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
Entering the document number in the space provided will display the details of the document.
This document number can be entered into the system in order to open the entry details anytime.
After that, the invoices are sent for binding and sent to the record room.
There are statutory requirements by the regulatory authority for Ranbaxy to maintain their
records for last 10 years.
If the entries are not posted due to some discrepancy:
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 51
-
8/8/2019 Final 14th
52/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
The pending invoices are opened up in the SAP system in order to find out the reasons for
mismatch. I came across some of the following cases while going through the invoices:
Difference in rates per unit charged by the vendor and that mentioned in the Purchase Order.
Discrepancy in the Tax code.
Difference in the Quantity mentioned in the invoice and that uploaded in the system.
Difference in Cenvat actually availed and that mentioned in the invoice.
If the difference in rates is minor and can ignorable, the same is rectified and the invoice is
passed. If the rate quoted by the vendor is higher, the same is rectified in the invoice and a brief
message indicating the same discrepancy is sent to the vendor so that he can identify the reason
for difference in the amount of payment asked for and actually received and makes required
changes in his books of accounts.
On the contrary, if the rated quoted by the vendor in the invoice is lower than that mentioned in
the system, the records in the system are adjusted and such lower amount is released for
payment to the vendor.
Such discrepant invoices are displayed in the list displayed of the posted but not passed invoices.
The following two is the stage of displaying the list:
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 52
-
8/8/2019 Final 14th
53/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
After displaying the list, each file can be separately viewed in detail and discrepancies can be
resolved.
In case there is a major discrepancy in the rates quoted by the vendor and those mentioned in the
Purchase Order or if there is a discrepancy in tax code, such cases are noted down in a PO
Discrepancy file. This file is prepared by the CMA department on a daily basis in order to bring
the reasons of mismatch, if any, to the notice of the Purchase department.
Discrepancies about the quantity, if any, can be clarified by viewing the Goods receipt note by
entering the GRN number in the following screen:
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 53
-
8/8/2019 Final 14th
54/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
Generally, tax code discrepancies occur due to the fact that there are different tax implications
for different goods and the excise rates applicable to different goods are different respectively.
This file reports the following information to the Purchase department:
Location
Vendor Name
Purchase Order number
Ownership Manager (the person who has created the Purchase Order)
Reference / Bill number
Challan number
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 54
-
8/8/2019 Final 14th
55/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
Pricing conditions as per Purchase Order (PO)
Prices as charged by the Vendor
Purchase Department remarks
RELEASE OF PAYMENTS:
As per a rule, payment run is executed twice a week i.e. every Monday and Thursday which
displays the vendors to whom the payments are due by the mentioned dates along with their
payment terms.
The payments are then processed rectifying the actual amount due to the creditors i.e. it may so
happen that some advance payments have been received from the vendor or any prior amount isdue towards him. Such adjustments are made before releasing the final payments through the
Bankers of the company.
BANKERS: ABN AMRO Bank NV. Standard Chartered Bank, Bank of America NA, Citibank
NA, Deutsche Bank AG, Hong Kong & Shanghai Banking Corporations, Punjab National Bank,
credit Lyonnais.
Freight Clearing:
Apart from invoice verification, I also dealt with a bit of freight clearing in my organization.
Freight clearing means clearing freight, as sometimes some unnecessary expenses do occur in
the system which have to be eliminated therein and then to avoid any further liability on the part
of the organization.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 55
-
8/8/2019 Final 14th
56/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
Ill be explaining this concept with the help of an example:
For example the company is purchasing a fridge, so first of all purchase order will be raised.
The total costs of fridge will be as follows:
Basic Cost 100
Freight 5
Octroi 2
Insurance 1
Other Expenses 5
Total - 113 (+CST/VAT whichever is applicable)
Now when the order has been raised the goods receipt come in the factory premises. And the
following entry is passed:
Inventory A/c Dr. 113
To liability for expenses A/c Cr. 100
To Freight A/c Cr. 5
To Octroi A/c Cr. 2
To Insurance A/c Cr. 1
To other expenses A/c Cr. 5
When the bill payment is made to the vendor, the following entry is passed:
Liability for expenses A/c Dr. 100
Freight A/c Dr. 5
Octroi A/c Dr. 2
To Vendor A/c Cr. 107
Now, initially the PO was raised was raised for 113 but the payment to the vendor has been
made for 107, so there lies a difference of 6Rs.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 56
-
8/8/2019 Final 14th
57/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
So difference of 6Rs. becomes our dummy liability for expenses. And the followingentries are
passed:
Other cost/freight/Octroi/Insurance A/c Dr. 6
To Dummy Vendor A/c Cr. 6
Dummy Vendor A/c Dr. 6
To Consumption A/c Cr. 6
The difference amount sometimes comes because the Purchase Departments who are making the
POs are fully not aware of the conditions.
The regular POs are written off with full value as done in the above example; however the
capex POs are written off with zero value.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 57
-
8/8/2019 Final 14th
58/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
LIMITATIONS & SHORT-COMINGS
While working in the payables section at CMA department-Ranbaxy, I came across thefollowing limitations and bottle necks in the process of Invoice verification:
There is lack of uniformity or synchronization between the Purchase department and thepayables section (where the process of Invoice verification is carried on) i.e. many ithappens that there are errors on part of the Purchase department while uploading theterms fixed up with the Vendors which have to be rectified by the Payables staff in orderto release the payments if all the details are in conformity with the Purchase Order. Incase there are errors, such information has been to be sent to the Purchase departmentagain after preparing a PO discrepancy file and the Purchase department reverts back.This delays the payment approval for vendors even if their Invoice terms are fair.
There is lack of information on part of the vendors resulting from which there are errorsin the preparation of Invoices and which further hinders the process of InvoiceVerification e.g. Generally, it happens in the organization that the tax codes applicablefor trading with a trader are not taken care of and mentioned wrongly on the invoices.Such errors lead to delay in Invoice verification and the re-consideration of invoices incase the vendor asks for a retrospective effect of the tax payments afterwards.
Efficiency falls to a great extent due the technical errors in the system. These errors referto the following:
The SAP server goes low due to the exhaustive load on a single server. There is lack of machines at disposal because of which the speed of work goes down. The hardware provided to the staff is not up to the mark which adversely affects the
efficiency to a great extent.
The employees performing Invoice verification are over-loaded with work. It includessmall jobs that could be performed at one stage before the Invoice verification.
The Tax codes could not be mentioned as it against the Privacy policy of theorganization.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 58
-
8/8/2019 Final 14th
59/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
RECOMMENDATIONS
The following suggestions if found practically feasible and technically applicable by the
management could be implemented in order to remove the bottlenecks and enhance the
efficiency of the process:
The payment terms should be intimated to the vendor very well in advance in a written
form failing to abide by which the vendor could be penalized in form of lower amount ofpayment or non-payment. This would help in reducing errors on part of the vendors
while preparing the invoices.
A detailed note of all the payment terms fixed up at the time of negotiations with the
respective vendors of different plant locations should be sent to the companied person so
that in case of discrepancy, the differences could be sorted there and then. This note
needs a careful verification so that the details included are authenticated and do not
intricate the procedure further when a discrepancy arises.
There can another stage added to the process where invoices can be properly sorted. This
sorting should include:
Plant wise Material code wise
Party wise
The machines provided to the staff should be increased in number and improved in
quality.
By this, I want to stress upon their regular upgrading so the working efficiency of the employees
could be improved.
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 59
-
8/8/2019 Final 14th
60/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
ANNEXURES
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 60
-
8/8/2019 Final 14th
61/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
RANBAXY
YEARS DEC'07 DEC'06 DEC'05 DEC'04 DEC'03
Fixed Assets 1469.5 1434 1200 877.58 717.52
Current Assets 2830.1 2509 2270.4 2308.22 2452.8
Current Liab 1572.4 1246.9 1142.6 1361.53 1122.5
Inventory 976.07 954.91 890.93 896.33 704.73
Debtors 882.91 1013.8 806.62 784.68 482.94
Loans& Advances 790.65 469.18 456.23 589.94 1166.6
Share capital 186.54 186.34 186.22 185.89 185.54
Reserves 2350.7 2162.8 2190.8 2320.79 2134.2
Secured loans 365.06 224.29 353.49 133.37 30.5
Usecured loans 3138 2954.3 676.31 2.49 3.76
total assets 6040.2 5527.7 3406.8 2642.55 2354
PBIT/operating profit 970.84 593.29 303.78 699.88 1019.8
Fixed interest charges 93.43 58.45 26.41 10.98 8.08
Gross profit 877.41 534.84 277.37 688.9 1011.7PAT 617.72 380.54 223.69 528.47 794.78
Sales 4428.6 4047.2 3575.4 3706.3 3637.6
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 61
-
8/8/2019 Final 14th
62/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
DEC'07 DEC'06 DEC'05 DEC'04 DEC'03
current ratio 1.7998 2.0122 1.9871 1.69531 2.1851
quick ratio 1.1791 1.2464 1.2073 1.03699 1.5573debtor turnovr 5.0159 3.9923 4.4326 4.72333 7.5322
inventory turnovr 4.5371 4.2383 4.0132 4.13497 5.1617
sales to workig capital 3.5213 3.2067 3.1702 3.91501 2.7344
debt equity ratio 1.3807 1.3531 0.4332 0.0542 0.0148
funded debt to total capitalization 57.995 57.503 30.228 5.14127 1.4554
proprietory ratio 0.4201 0.425 0.6977 0.94859 0.9854
solvency ratio 0.5799 0.575 0.3023 0.05141 0.0146
fixed assets to net worth ratio 0.5792 0.6105 0.5048 0.3501 0.3093
interest coverage ratio 10.391 10.15 11.502 63.7413 126.21
G.P.Ratio 19.813 13.215 7.7576 18.5873 27.812
operating profit ratio 21.922 14.659 8.4963 18.8835 28.034
Net profit Ratio 13.949 9.4027 6.2563 14.2587 21.849
Cipla
Years Mar-08 Mar-07 Mar-06 Mar-05 Mar-04 Mar-03
Fixed Assets1661.3
61388.0
71056.6
1 738.91 547.56 371.05
Current Assets3743.9
82834.6
82292.2
91749.0
41436.2
3 1291.1
Current Liab1247.7
1 941.26 908.21 778.44 679.59 596.61
Inventory1120.4
9 978.6 957 745.68 568.94 589.23
Debtors1393.9
11028.7
8 875.96 587.32 498.23 355.37
Loans& Advances 1150.3 695.81 414.85 404.84 362.82 333.38
Share capital 155.46 155.46 59.97 59.97 59.97 59.97
Reserves 3600.36 3080.81 1923.3 1493.66 1204.08 1010.11
Secured loans 16.98 7.25 51.27 41.24 30.6 28.89
Usecured loans 563.55 116.31 417.64 149.96 179.98 65.89Total Assets 4336.3 3359.8 2452.1 1744.8 1474.8 1164.8
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 62
-
8/8/2019 Final 14th
63/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
5 3 8 3 3 6
PBIT/OP Profit 987.09 922.51 806.09 581.32 448.19 345.34
Fixed interest charges 18.05 11.16 16.07 11.66 13.47 4.49Gross profit 969.04 911.35 790.02 569.66 434.72 340.85
PAT 701.43 668.03 607.64 409.61 306.69 247.74
Sales 3997.93438.2
42891.3
62181.2
61842.2
41437.2
8
Years Mar-08 Mar-07 Mar-06 Mar-05 Mar-04 Mar-03
current ratio3.0006
83.0115
82.5239
62.2468
52.1133
82.1640
6
quick ratio
2.1026
4
1.9719
1
1.4702
4
1.2889
4 1.2762
1.1764
3
debtor turnovr2.8681
23.3420
63.3007
93.7139
23.6975
74.0444
6
inventory turnovr3.5679
93.5134
33.0212
7 2.92523.2380
22.4392
5
sales to workig capital1.6015
51.8158
92.0890
12.2473
32.4347
62.0695
5
debt equity ratio0.1545
70.0381
80.2364
30.1230
70.1665
90.0885
7funded debt to totalcapitalization
13.3875
3.67757
19.1222
10.9581
14.2802 8.1366
proprietory ratio0.8661
20.9632
20.8087
80.8904
20.8570
80.9186
3
solvency ratio0.1338
80.0367
80.1912
20.1095
80.1427
80.0813
7
fixed assets to net worth ratio0.4423
40.4289
10.5327
6 0.47560.4331
80.3467
5
interest coverage ratio54.686
482.662
250.161
249.855
933.273
276.913
1
G.P.Ratio24.238
726.506
327.323
526.116
123.597
423.714
9
operating profit ratio
24.690
2
26.830
9
27.879
3
26.650
7
24.328
5
24.027
3
Net profit Ratio 17.54519.429
421.015
718.778
616.647
717.236
7
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 63
-
8/8/2019 Final 14th
64/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
Dr.Reddy
Years Mar-08 Mar-07 Mar-06 Mar-05 Mar-04 Mar-03
Fixed Assets 987.42 682.04 561.81 562.54 458.1 395.76
Current Assets3329.3
63987.6
42380.9
71948.1
71321.6
31547.7
8
Current Liab1132.1
3 1019.5 638.4 560.82 349.53 273.57
Inventory 640.93 487.58 443.1 303.81 258.01 240.11
Debtors 897.71 1055.7 581.21 417.64 444.05 432.45
Loans& Advances1253.3
8 987.65 705.72 335 211.49 186.82
Share capital 84.09 83.96 38.35 38.26 38.26 38.26
Reserves4727.7
2 4289.42223.7
92035.8
22008.7
61768.6
6
Secured loans 3.4 1.92 145.13 3.27 35.64 4.29
Usecured loans 458.91 327.98 778.74 269.97 22.58 24.47
Total Assets4336.3
53359.8
32452.1
81744.8
31474.6
31164.8
6
PBIT/OP Profit 760.781551.3
1 399.71 149.56 379.3 498.05
Fixed interest charges 14.69 51.96 24.62 12.74 4.23 6.05
Gross profit 746.09
1499.3
5 375.09 136.82 375.07 492
PAT 475.221176.8
6 211.12 65.46 283.2 392.09
Sales 3365.23955.6
62005.8
51549.9
81661.2
21513.6
1
Years Mar-08 Mar-07 Mar-06 Mar-05 Mar-04 Mar-03
current ratio2.9407
93.9113
73.7295
93.4737
93.7811
65.6577
1
quick ratio2.3746
73.4331
13.0355
12.9320
6 3.0434.7800
2
debtor turnovr3.7486
53.7469
53.4511
63.7112
83.7410
73.5000
8
inventory turnovr 5.25058.1128
44.5268
65.1018
16.4385
96.3038
2
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 64
-
8/8/2019 Final 14th
65/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
sales to workig capital1.5315
61.3327
11.1510
91.1172
2 1.70891.1878
8
debt equity ratio
0.0960
8
0.0754
3
0.4084
1
0.1317
4
0.0284
4
0.0159
2funded debt to totalcapitalization
8.76563
7.01428
28.9977
11.6405
2.76548
1.56672
proprietory ratio1.1096
51.3016
6 0.9225 1.18871.3881
61.5511
9
solvency ratio0.1066
10.0981
90.3767
5 0.15660.0394
80.0246
9
fixed assets to net worth ratio0.2052
10.1559
50.2483
50.2712
20.2237
90.2190
2
interest coverage ratio 51.78929.855
916.235
211.739
4 89.66982.322
3
G.P.Ratio22.170
737.903
918.699
88.8272
1 22.57832.505
1
operating profit ratio22.607
339.217
519.927
29.6491
622.832
632.904
8
Net profit Ratio14.121
629.751
310.525
24.2232
817.047
725.904
3
Lupin
Years Mar-08 Mar-07 Mar-06 Mar-05 Mar-04 Mar-03
Fixed Assets 863.07 713.81 642.4 558.94 517.21 485.65
Current Assets 1727.95 1475.53 1314.17 673.87 646.15 858.59
Current Liab 438.37 355.67 299.54 239.64 196.73 183.05
Inventory 625.85 402.07 310.29 248.08 215.3 141.86
Debtors 632.26 479.3 348.39 235.39 215.83 402.22
Loans& Advances 254.76 241.38 199.69 172.62 199.98 299.72
Share capital 82.08 80.34 40.14 40.14 40.14 40.14
Reserves 1234.97 808.07 603.81 460.36 407.89 342.23Secured loans 560.88 390.91 428.65 380.63 286.55 550.92
Usecured loans 404.67 473.64 483.95 60.01 90.56 100.01
Total Assets 2282.6 1752.96 1556.55 941.14 825.14 1033.3
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 65
-
8/8/2019 Final 14th
66/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
PBIT/OP Profit 648.14 480.21 300.85 145.79 229.28 185.42
Fixed interest charges 34.39 37.09 30.3 27.31 51.51 63.32
Gross profit 613.75 443.12 270.55 118.48 177.77 122.1PAT 443.38 302.06 182.72 84.36 98.71 73.07
Sales 2523.63 1962.96 1596.54 1155.76 1147.25 939.05
YearsMAR'08
MAR'07
MAR'06
MAR'05
MAR'04
MAR'03
CURRENT RATIO 3.94 4.15 4.39 2.81 3.28 4.69
quick ratio 2.51409 3.01813 3.35141 1.77679 2.19006 3.91549
debtor turnovr 3.99144 4.09547 4.58262 4.90998 5.31553 2.33467
inventory turnovr 4.03232 4.88213 5.14532 4.65882 5.32861 6.61955
sales to workig capital 1.95694 1.75286 1.57352 2.66163 2.55273 1.39007debt equity ratio 0.73312 0.97314 1.41719 0.8804 0.84171 1.70236funded debt to totalcapitalization 42.3004 49.3194 58.6297 46.8198 45.7025 62.9953
proprietary ratio 0.577 0.50681 0.4137 0.5318 0.54297 0.37005
solvency ratio 0.423 0.49319 0.5863 0.4682 0.45703 0.62995
fixed assets to net worth ratio 0.65531 0.80347 0.99759 1.11676 1.15441 1.2701
interest coverage ratio 18.8468 12.9472 9.92904 5.33834 4.45117 2.9283
G.P.Ratio 24.3201 22.5741 16.946 10.2513 15.4953 13.0025
operating profit ratio 25.6828 24.4636 18.8439 12.6142 19.9852 19.7455
Net profit Ratio 17.5691 15.388 11.4447 7.29909 8.60405 7.78127
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 66
-
8/8/2019 Final 14th
67/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 67
-
8/8/2019 Final 14th
68/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 68
-
8/8/2019 Final 14th
69/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
RANBAXY LABORATORIES LIMITEDFINANCIAL ANALYSIS Page 69
-
8/8/2019 Final 14th
70/70
ICFAI BUSINESS SCHOOL, CHANDIGARH
References:
Balance sheet 2003-07
Profit & loss Account, 2003-07
Files, books and journals of Ranbaxy &SAP literature
Shashi K. Gupta, R.K. Sharma, Management Accounting(12th edition), Kalyani Publishers
ICMR, Financial Management, ICFAI University
www.ranbaxy.com
www.google.com
www.anagram.co.in
www.pharmaceutical-drug-manufacturers.com
Wikipedia.org
Balance sheets and Income Statements of Cipla, Dr,Reddy, Lupin and Ranbaxy for the last five
years i.e. 2003-07
http://www.ranbaxy.com/http://www.google.com/http://www.anagram.co.in/http://www.pharmaceutical-drug-manufacturers.com/http://www.ranbaxy.com/http://www.google.com/http://www.anagram.co.in/http://www.pharmaceutical-drug-manufacturers.com/